ClinGen Dosage Sensitivity Curation Page

See New Dosage Map New! The ClinGen Dosage Sensitivity curations and downloads that are available at this site are now also available at www.clinicalgenome.org. Click on the button to access Dosage Sensitivity in the context of ClinGen's other curated information, including Gene-Disease Validity and Clinical Actionability.

DMXL2

  • Curation Status: Complete

Location Information

Select assembly: (NC_000015.9) (NC_000015.10)
  • Haploinsufficiency score: 0
  • Strength of Evidence (disclaimer): No evidence for dosage pathogenicity

Haploinsufficiency phenotype comments:

Note: There are 2 reports of chimeric transcripts between CYP19 and DMXL2 which propose a gain of function for these mutations. PMID:17584767 Demura et al. (2007) examined 3 families and 2 sporadic cases with aromatase excess syndrome. CYP19 encodes aromatase, and gain of function mutations cause this syndrome. The authors describe a family with aromatase excess syndrome that have an abnormal chimeric CYP19 mRNA that is fused with exon 1 of DMXL2 (normally ~380 kb upstream of CYP19). They performed real-time PCR on 7 segments of DNA from exon 2 of DMXL2 to CYP19. In the affected mom and son, they found a ~145 kb deletion that includes exon 2 DMXL2 through the last exon of the gene. PMID:21470988 Fukami et al. (2011) identified chimeric transcripts in families with AES. They identified a ~212 kb deletion involving exons 2-43 of DMXL2 along with exons 5-10 of GLDN in one family. In three additional families, they identified a ~166 kb deletion involving exons 2-43 of DMXL2. These deletions resulted in a chimeric transcript including exon 1 of DMXL2 and CYP19A1 coding exons.

  • Triplosensitivity score: 0
  • Strength of Evidence (disclaimer): No evidence for dosage pathogenicity